# Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00719901** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** obatoclax mesylate
- **DRUG:** bortezomib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00719901
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2011-04
- **Final completion:** 2012-06
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open.
- **Last updated:** 2015-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00719901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00719901, "Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00719901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*